Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5021080 | 0.88 | L3MBTL1 (0.56) | CYP19A1L3MBTL1HRH4HRH3GGPS1 | |
| SCHEMBL14982736 | 0.87 | CYP19A1 (0.50) | CYP19A1L3MBTL1HRH4HRH3GGPS1 | |
| SCHEMBL15042747 | 0.87 | CYP19A1 (0.61) | CYP19A1L3MBTL1HRH4HRH3GGPS1 | |
| SCHEMBL3549774 | 0.86 | CYP19A1 (0.62) | CYP19A1L3MBTL1HRH4HRH3GGPS1 | |
| SCHEMBL5021089 | 0.85 | CYP19A1 (0.59) | CYP19A1HRH4HRH3GBA1 | |
| SCHEMBL3546675 | 0.84 | CYP19A1 (0.65) | CYP19A1L3MBTL1HRH4HRH3GGPS1 | |
| SCHEMBL22701235 | 0.84 | CYP19A1 (0.65) | CYP19A1L3MBTL1HRH4HRH3GGPS1 | |
| SCHEMBL22794232 | 0.84 | CYP19A1 (0.65) | CYP19A1L3MBTL1HRH4HRH3GGPS1 | |
| SCHEMBL25837226 | 0.84 | CYP19A1 (0.65) | CYP19A1L3MBTL1HRH4HRH3GGPS1 | |
| SCHEMBL25836828 | 0.84 | CYP19A1 (0.65) | CYP19A1L3MBTL1HRH4HRH3GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833229-B2 | Labeling precursors with squaric acid coupling | SCV SPEZIAL-CHEMIKALIEN-VERTRIEBS GMBH (DE) | 2023-12-05 | — | — | US | disclosed |
| EP-3555082-B1 | ETHER LINKED TRIAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-26 | — | — | EP | disclosed |
| WO-2021262587-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED (US) | 2021-12-30 | — | — | WO | disclosed |
| US-10870642-B2 | Biheterocyclic compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-12-22 | — | — | US | disclosed |
| WO-2019192532-A1 | BLADDER CANCER PHOTODYNAMIC THERAPEUTIC AGENTS WITH OFF-ON MAGNETIC RESONANCE IMAGING ENHANCEMENT | HONG KONG BAPTIST UNIVERSITY (CN) | 2019-10-10 | — | — | WO | disclosed |
| US-20190308958-A1 | BIHETEROCYCLIC COMPOUND | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-10-10 | — | — | US | disclosed |
| WO-2018109643-A1 | BISARYL HETEROCYCLES AS NRF2 ACTI | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-04-05 | — | — | US | disclosed |
| EP-3301108-A1 | TRIAZOLE MACROCYCLE SYSTEMS | Aileron Therapeutics, Inc. (US) | 2018-04-04 | — | — | EP | disclosed |
| EP-2342222-B1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20160282357-A1 | METHODS AND COMPOSITIONS RELATED TO NUCLEIC ACID BINDING ASSAYS | Nubad, LLC | 2016-09-29 | — | — | US | disclosed |
| US-20160031926-A1 | Triazole Compounds and Methods of Making and Using the Same | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-9006189-B2 | Triazole compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140088031-A1 | Triazole Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20130065845-A1 | Triazole Compounds and Methods of Making and Using the Same | BioVersys AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-8278281-B2 | Triazole compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-08-16 | — | — | US | disclosed |
| US-8158590-B2 | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation | SYNTARGA B.V. (NL) | 2012-04-17 | — | — | US | disclosed |
| US-20120046461-A1 | STEROIDAL ANTI-HORMONE HYBRIDS | NORTHEASTERN UNIVERSITY (US) | 2012-02-23 | — | — | US | disclosed |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | BYONDIS B.V. (NL) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | CYP19A1 1883/4885L3MBTL1 1895/4885HRH4 3631/4885 |
| US-20120046461-A1 | STEROIDAL ANTI-HORMONE HYBRIDS | ESRRA, ESRRB, NR5A1 | CYP19A1 25/4885L3MBTL1 4228/4885HRH4 2718/4885 |
| US-20180094016-A1 | Triazole Compounds And Methods Of Making And Using The Same | IL33, PROKR1, VIP | CYP19A1 2296/4885L3MBTL1 3531/4885HRH4 320/4885 |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | PAICS, CD44, TRIM33 | CYP19A1 2443/4885L3MBTL1 1945/4885HRH4 1571/4885 |
| US-20130065845-A1 | Triazole Compounds and Methods of Making and Using the Same | IL33, PROKR1, VIP | CYP19A1 2296/4885L3MBTL1 3531/4885HRH4 320/4885 |
| US-20190308958-A1 | BIHETEROCYCLIC COMPOUND | NR4A3, NGF, OGFR | CYP19A1 450/4885L3MBTL1 404/4885HRH4 198/4885 |
| US-20160031926-A1 | Triazole Compounds and Methods of Making and Using the Same | IL33, PROKR1, VIP | CYP19A1 2296/4885L3MBTL1 3531/4885HRH4 320/4885 |
| US-20140088031-A1 | Triazole Compounds and Methods of Making and Using the Same | IL33, PROKR1, VIP | CYP19A1 2296/4885L3MBTL1 3531/4885HRH4 320/4885 |
| US-10870642-B2 | Biheterocyclic compound | NR4A3, NGF, OGFR | CYP19A1 450/4885L3MBTL1 404/4885HRH4 198/4885 |
| US-11833229-B2 | Labeling precursors with squaric acid coupling | SCLY, SRRT, CS | CYP19A1 1570/4885L3MBTL1 1353/4885HRH4 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.